

PRESS RELEASE

ASTRAZENECA INVESTS VND5 TRILLION IN VIETNAM

Investment will support people's health by accelerating healthcare capacity development, R&D and talent development

May 27, 2019, Södertälje, Sweden, AstraZeneca today announced a five-year investment of VND5 trillion (ca.US\$220 million, 2020-2024) in Vietnam during Prime Minister Nguyen Xuan Phuc's visit to Sweden. The investment, which was announced at AstraZeneca's main manufacturing site in Södertälje in the presence of the Prime Minister and representatives from the Swedish government, underpins AstraZeneca's commitment to the Vietnamese government's call for all healthcare partners to strive for better health for the Vietnamese people, as expressed in the 2017 resolutionⁱ and the recently launched "*Vietnam Health Programme*".

The investment accelerates AstraZeneca's existing efforts to expand access to healthcare and to improve the quality of healthcare delivery for Vietnamese patients. This will also ensure that the company continues to develop high value employment.

AstraZeneca aims to play a leading role in reducing the prevalence of Non-Communicable Diseases (NCDs), which accounted for 318,000 deaths (72% of total deaths) annually, which in turn implies 6.7 million years of life lost, and 14 million disability-adjusted life yearsⁱⁱ. Part of the commitment includes the implementation of the Young Health Programme (YHP) to improve the management and control of NCDs. AstraZeneca, Plan International, the National Youth Centre and the Hanoi Centre for Disease Prevention and Control (HNCCDC) are partnering to empower young people and their communities to make healthy choices in diet, exercise and lifestyle. In the next three years, YHP aims to educate over 46,000 directly from 27 schools and universities and 100,000 youths indirectly on risk factors surrounding NCDs such as diabetes and cancer.ⁱⁱⁱ

This new collaboration is built on the company's ambition to work with external partners to expand the healthcare capacity development in Vietnam, which has seen recent successful milestone initiatives such Healthy Lung Vietnam that addresses asthma and COPD management and as well Early Action in Diabetes, a programme that aims to increase early diagnosis to prevent complications surrounding diabetes.

In addition, AstraZeneca will continue to drive the development of biomedical science and innovation in Vietnam through clinical research and R&D. The data from these research programmes will enable future medicines to better address the needs of Vietnamese patients and provide an uplift in the biomedical expertise in the country. AstraZeneca has been the leading initiator of clinical research in Vietnam in the past five years^{iv}, AstraZeneca looks forward to expanding its collaboration with its robust network of more than 130 research sites nationwide^v.

AstraZeneca intends to establish innovation programme to collaborate with competent Vietnamese entities/agencies and/or organisations to work on research and innovation projects. The company will continue to invest in training and improving the capacity of Healthcare Practitioners at primary care or grassroot levels to increase early diagnosis and provide the right treatment for patients.

As a final component of AstraZeneca's commitment, the company will provide over 500 high-quality jobs in biomedical sciences and medical affairs, as well as sales and marketing through the 3rd party. By giving Vietnamese talented professionals development opportunities and exposure to AstraZeneca's global operations, the company aims to increase national biomedical skills and drive forward Vietnam's medical and economic development.

Mr. Leif Johansson, Chairman of AstraZeneca, said: "*AstraZeneca is proud to have been present in Vietnam for 25 years. Through this investment, we strengthen our commitment to work with our partners to improve healthcare for the people in Vietnam. We look forward to working with the government, hospitals and other partners to lift Vietnam's healthcare capability to world-class levels and reach the goals of the UN 2030 Agenda for Sustainable Development.*"

Nitin Kapoor, Company President of AstraZeneca in Vietnam, said “*I am honoured to lead the implementation of this new phase of our operations in Vietnam. As a global biopharmaceutical company with strong roots in Sweden and the UK, we are proud to continue to partner with the Vietnamese Government and healthcare organisations that place people’s health as a top priority. We are passionate about transforming the lives of patients with diseases such as diabetes, asthma and cancer and, with the new investment, are excited about accelerating our efforts nationwide.*”

- End -

Notes:

Healthy Lung Vietnam: Launched in 2017, AstraZeneca is currently partnering with the Ministry of Health’s Medical Service Administration (MSA) and other partners to improve the quality of outpatient management of asthma and Chronic Obstructive Pulmonary Disease (COPD) through Healthy Lung Vietnam over three years. AstraZeneca aims to establish 150 Units of Management Asthma and COPD (UMAC), raise right awareness of community on asthma and chronic obstructive pulmonary disease, improve capabilities for health care workers in asthma and chronic obstructive pulmonary disease diagnosis and management. To date, 2,500 physicians have been trained and 9,105 patients have been educated, and 4,036 patients screened through this programme^v.

Early Action in Diabetes: AstraZeneca partnered with the Vietnam Young Physicians Association (VYPA) to host Community Day, focused on The Family & Early Action in Diabetes in Ha Noi and Ho Chi Minh City. The event provided free screening for approximately 1,000^v people at risk of diabetes and helped to prevent, detect early and treat adequately this increasingly prevalent disease. In the coming years, AstraZeneca will continue to collaborate with healthcare organizations to increase the community awareness nationwide about Diabetes – its complications need to be detected and controlled.

Young Health Programme: The Young Health Programme (YHP) is a global community investment programme focused on youth and prevention of the most common non-communicable diseases (NCDs): cancer, diabetes, heart disease and respiratory disease. Developed in partnership with Johns Hopkins Bloomberg School of Public Health and Plan International, it aims to reduce the uptake of unhealthy behaviours in young people that can lead to NCDs later in life. These behaviours include tobacco use, the harmful use of alcohol, unhealthy diet and lack of exercise activity.^(vi)

More info about Young Health Program, please go to the website:
<https://www.younghealthprogrammehp.com/programmes/Vietnam.html>

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

ⁱ Central Committee Communist Party of Vietnam’s Resolution No.20-NQ/TW

ⁱⁱ Tuan T Nguyen; Minh V Hoang (2018). Non-communicable diseases, food and nutrition in Vietnam from 1975 to 2015: the burden and national response. *Asia Pac J Clin Nutr* 2018;27(1):19-28 – Page 1

ⁱⁱⁱ Plan International – YHP Vietnam Proposal - Page 33

^{iv} www.clinicaltrials.gov

^v Data on file

^{vi} <https://www.younghealthprogrammehp.com/>